SG11201604839XA - Wnt pathway modulators - Google Patents
Wnt pathway modulatorsInfo
- Publication number
- SG11201604839XA SG11201604839XA SG11201604839XA SG11201604839XA SG11201604839XA SG 11201604839X A SG11201604839X A SG 11201604839XA SG 11201604839X A SG11201604839X A SG 11201604839XA SG 11201604839X A SG11201604839X A SG 11201604839XA SG 11201604839X A SG11201604839X A SG 11201604839XA
- Authority
- SG
- Singapore
- Prior art keywords
- wnt pathway
- pathway modulators
- modulators
- wnt
- pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322333.4A GB201322333D0 (en) | 2013-12-17 | 2013-12-17 | WNT pathway modulators |
| PCT/SG2014/000602 WO2015094119A1 (en) | 2013-12-17 | 2014-12-17 | Wnt pathway modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604839XA true SG11201604839XA (en) | 2016-07-28 |
Family
ID=50031066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604839XA SG11201604839XA (en) | 2013-12-17 | 2014-12-17 | Wnt pathway modulators |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10189842B2 (zh) |
| EP (1) | EP3083631B1 (zh) |
| JP (1) | JP6452703B2 (zh) |
| KR (1) | KR102383739B1 (zh) |
| CN (1) | CN105992767B (zh) |
| AU (1) | AU2014367284B2 (zh) |
| BR (1) | BR112016013640A8 (zh) |
| CA (1) | CA2933683A1 (zh) |
| DK (1) | DK3083631T3 (zh) |
| ES (1) | ES2687493T3 (zh) |
| GB (1) | GB201322333D0 (zh) |
| SG (1) | SG11201604839XA (zh) |
| WO (1) | WO2015094119A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322333D0 (en) | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | WNT pathway modulators |
| GB201414730D0 (en) * | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
| CN106795157B (zh) * | 2014-10-08 | 2019-07-23 | 莱德克斯制药公共有限公司 | 作为Wnt信号传送途径的抑制剂的N-吡啶基乙酰胺衍生物 |
| US10626368B2 (en) * | 2015-04-14 | 2020-04-21 | Kyoto University | Method for inducing cerebral cortex neurons |
| KR20200135463A (ko) * | 2018-03-23 | 2020-12-02 | 스텝 파마 에스.에이.에스. | Ctps1 억제제로서 아미노피리미딘 유도체 |
| WO2019180244A1 (en) * | 2018-03-23 | 2019-09-26 | Step Pharma S.A.S. | Aminopyrimidine derivatives as ctps1 inhibitors |
| TWI804545B (zh) * | 2018-03-23 | 2023-06-11 | 法商史坦普醫藥簡式股份公司 | 化合物 |
| EA202191104A1 (ru) | 2018-10-23 | 2021-07-19 | Степ Фарма С.А.С. | Производные аминопиридина/пиразина в качестве ингибиторов ctps1 |
| CN111620874B (zh) * | 2019-02-28 | 2022-11-15 | 汇瀚医疗科技有限公司 | 取代5,6-双杂环氨基化合物作为wnt信号通路抑制剂及其治疗应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070219183A1 (en) * | 2006-03-17 | 2007-09-20 | Wyeth | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof |
| EP1918291A1 (en) * | 2006-10-30 | 2008-05-07 | Novartis AG | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators |
| CN101906105B (zh) | 2009-06-08 | 2013-01-16 | 河北医科大学 | 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途 |
| WO2011121096A1 (en) * | 2010-03-31 | 2011-10-06 | Dkfz Deutsches Krebsforschungszentrum | PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS |
| WO2011156632A2 (en) * | 2010-06-09 | 2011-12-15 | Georgetown University | Compositions and methods of treatment for tumors in the nervous system |
| AU2013212175B2 (en) * | 2012-01-28 | 2017-03-02 | Cancer Research Technology Limited | Azaheterocyclic compounds |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| US20150157633A1 (en) * | 2012-05-11 | 2015-06-11 | The Board Of Regents Of The University Of Texas System | Wnt protein signalling inhibitors |
| GB201322333D0 (en) | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | WNT pathway modulators |
-
2013
- 2013-12-17 GB GBGB1322333.4A patent/GB201322333D0/en not_active Ceased
-
2014
- 2014-12-17 BR BR112016013640A patent/BR112016013640A8/pt not_active IP Right Cessation
- 2014-12-17 CN CN201480075676.5A patent/CN105992767B/zh active Active
- 2014-12-17 DK DK14870867.0T patent/DK3083631T3/en active
- 2014-12-17 CA CA2933683A patent/CA2933683A1/en not_active Abandoned
- 2014-12-17 ES ES14870867.0T patent/ES2687493T3/es active Active
- 2014-12-17 SG SG11201604839XA patent/SG11201604839XA/en unknown
- 2014-12-17 US US15/105,224 patent/US10189842B2/en active Active
- 2014-12-17 JP JP2016540531A patent/JP6452703B2/ja active Active
- 2014-12-17 EP EP14870867.0A patent/EP3083631B1/en active Active
- 2014-12-17 AU AU2014367284A patent/AU2014367284B2/en active Active
- 2014-12-17 WO PCT/SG2014/000602 patent/WO2015094119A1/en active Application Filing
- 2014-12-17 KR KR1020167019109A patent/KR102383739B1/ko active IP Right Grant
-
2018
- 2018-12-19 US US16/226,398 patent/US10870653B2/en active Active
-
2020
- 2020-10-29 US US17/084,507 patent/US11434245B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014367284B2 (en) | 2019-01-17 |
| JP2016540803A (ja) | 2016-12-28 |
| KR20160124083A (ko) | 2016-10-26 |
| EP3083631A4 (en) | 2017-05-31 |
| US20170240550A9 (en) | 2017-08-24 |
| JP6452703B2 (ja) | 2019-01-16 |
| BR112016013640A2 (zh) | 2017-08-08 |
| CN105992767A (zh) | 2016-10-05 |
| EP3083631A1 (en) | 2016-10-26 |
| EP3083631B1 (en) | 2018-06-13 |
| US10870653B2 (en) | 2020-12-22 |
| US20160311829A1 (en) | 2016-10-27 |
| CN105992767B (zh) | 2019-06-21 |
| US20210047336A1 (en) | 2021-02-18 |
| CA2933683A1 (en) | 2015-06-25 |
| BR112016013640A8 (pt) | 2020-05-19 |
| DK3083631T3 (en) | 2018-09-24 |
| US20190185478A1 (en) | 2019-06-20 |
| WO2015094119A1 (en) | 2015-06-25 |
| AU2014367284A1 (en) | 2016-06-30 |
| GB201322333D0 (en) | 2014-01-29 |
| ES2687493T3 (es) | 2018-10-25 |
| US20180093988A9 (en) | 2018-04-05 |
| US10189842B2 (en) | 2019-01-29 |
| KR102383739B1 (ko) | 2022-04-05 |
| US11434245B2 (en) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171168T4 (hr) | Modulatori p2x7 | |
| HK1254111A1 (zh) | P2x7調節劑 | |
| HK1225638A1 (zh) | 補體因子b的調節劑 | |
| HK1232216A1 (zh) | 調製器 | |
| SG11201509593TA (en) | Purine diones as wnt pathway modulators | |
| HK1218651A1 (zh) | 調節劑 | |
| HK1217489A1 (zh) | 調節劑 | |
| SG11201604839XA (en) | Wnt pathway modulators | |
| EP2968275A4 (en) | MODULATORS OF LXR | |
| EP2968296A4 (en) | MODULATORS OF GAMMA-SECRETASE | |
| HK1218542A1 (zh) | 調節劑 | |
| EP2967073A4 (en) | MODULATORS OF LXR | |
| TWI560487B (en) | Electro-optical modulator | |
| GB201307564D0 (en) | WNT pathway modulator | |
| GB201321601D0 (en) | Modulator | |
| GB201312727D0 (en) | Modulators | |
| GB201318298D0 (en) | Modulators | |
| GB201317988D0 (en) | Modulators | |
| GB201304473D0 (en) | Modulators | |
| GB201314051D0 (en) | Novel DRAK modulators | |
| GB201310390D0 (en) | Modulator Assay |